Results 91 to 100 of about 37,133 (255)

Molecular–clinical characteristics and treatment outcomes in 163 metastatic colorectal neuroendocrine carcinomas with a comparison to colorectal adenocarcinomas

International Journal of Cancer, EarlyView.
What's New? Colorectal neuroendocrine carcinoma (CR‐NEC) is a rare digestive neuroendocrine neoplasm that frequently exhibits an adenocarcinoma component. Nonetheless, the underlying biology of CR‐NEC remains poorly understood. This study examined molecular and clinical features and palliative chemotherapy outcomes of metastatic CR‐NEC, with comparison
Siren Morken, Seppo W. Langer, Geir Olav Hjortland, Anna Sundlöv, Eva Hofsli, Morten Ladekarl, Elizaveta Tabaksblat, Lene Weber Vestermark, Johanna Svensson, Ulrich Knigge, Luís Nunes, Bengt Glimelius, Per Pfeiffer, Kristine Aasebø, Jörg Assmus, Erik Vassella, Inger Marie Bowitz Lothe, Anne Couvelard, Aurel Perren, Stian Knappskog, Halfdan Sorbye   +20 more
wiley   +1 more source

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated

Journal of Translational Medicine, 2020
Background Most mutations in melanoma affect one critical amino acid on BRAF gene, resulting in the V600E substitution. Patient management is often based on the use of specific inhibitors targeting this mutation.
Muna Al Hashmi, Konduru S. Sastry, Lee Silcock, Lotfi Chouchane, Valentina Mattei, Nicola James, Rebecca Mathew, Davide Bedognetti, Valeria De Giorgi, Daniela Murtas, Wei Liu, Aouatef Chouchane, Ramzi Temanni, Barbara Seliger, Ena Wang, Francesco M. Marincola, Sara Tomei   +16 more
doaj   +1 more source

Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas [PDF]

, 2018
FDA-approved BRAF inhibitors produce high response rates and improve overall survival in patients with BRAF V600E/K-mutant melanoma, but are linked to pathologies associated with paradoxical ERK1/2 activation in wild-type BRAF cells.
Aplin, Andrew E., Berger, Adam C., Bollag, Gideon, Davies, Michael A., Goldberg, Allison F., Hartsough, Edward J., Knudsen, Karen E., Kugel, Curtis H., Purwin, Timothy J., Schiewer, Matthew J., Vido, Michael J.   +10 more
core   +1 more source

Bisphenol A Induces DNA Damage and Differential Cytotoxicity in Thyroid Cells: High‐Dose Effects Challenge Regulatory Thresholds

Journal of Applied Toxicology, EarlyView.
ABSTRACT Bisphenol A (BPA), a ubiquitous environmental endocrine disruptor, has been implicated in carcinogenesis; however, its effects on thyroid cells remain unclear. This study investigated BPA‐induced cytotoxicity and genotoxicity in thyroid cell lines, including normal follicular (Nthy‐ori 3‐1), papillary carcinoma (TPC‐1 and BCPAP) and anaplastic
Izabela Fernanda Dal' Bó, Natássia Elena Bufalo, Valdemar Máximo, Laura Sterian Ward   +3 more
wiley   +1 more source

BRAF and TERT mutations in papillary thyroid cancer patients of Latino ancestry. [PDF]

, 2019
Papillary thyroid cancer (PTC) is the second most commonly diagnosed malignancy in U.S. Latinas and in Colombian women. Studies in non-Latinos indicate that BRAF and TERT mutations are PTC prognostic markers.
Bohórquez, Mabel E, Carvajal-Carmona, Luis G, Donado, Jorge H, Duque, Carlos S, Echeverry, Magdalena, Estrada-Flórez, Ana P, Mateus, Gilbert, Panqueba-Tarazona, Cesar, Polanco-Echeverry, Guadalupe, Sahasrabudhe, Ruta, Vélez, Alejandro   +10 more
core  

Emerging treatment options for BRAF-mutant colorectal cancer. [PDF]

, 2018
The personalization of cancer care is rooted in the premise that there are subsets of patients with tumors harboring clinically relevant targets for patient-specific treatments.
Atreya, Chloe E, Ursem, Carling, Van Loon, Katherine   +2 more
core   +2 more sources

Exome Sequencing Identifies Variants in MLH1 and ERBB2 as Potential Cancer‐Predisposing Factors in Familial Early‐Onset Colorectal Cancer

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Colorectal cancer (CRC) has raised considerable health concerns worldwide, with increasing incidence rates, specifically among younger populations. Despite remarkable progress in diagnosing and treating various diseases, the genetic basis of CRC remains only partially understood.
Behnaz Bagheri, Neda Mohsen‐Pour, Najmeh Salehi, Pardis Ketabi Moghadam, Adel Zeinalpour, Amir Sadeghi, Samira Kalayinia, Nayeralsadat Fatemi   +7 more
wiley   +1 more source

BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm

Journal of Otolaryngology - Head and Neck Surgery, 2021
Background While some studies suggest that the BRAF V600E mutation correlates with a high-risk phenotype in papillary thyroid microcarcinoma (PTMC), more evidence is necessary before this mutation can be used to help guide decision making in the ...
Jennifer A. Silver, Mariya Bogatchenko, Marc Pusztaszeri, Véronique-Isabelle Forest, Michael P. Hier, Ji Wei Yang, Michael Tamilia, Richard J. Payne   +7 more
doaj   +1 more source

Clinicopathological characteristics of circumscribed high-grade astrocytomas with an unusual combination of BRAF V600E, ATRX, and CDKN2A/B alternations. [PDF]

, 2019
学位記番号 ...
Murakami, Chiaki, ムラカミ, チアキ, 村上, 千明   +2 more
core  

MicroRNA-203 predicts human survival after resection of colorectal liver metastasis. [PDF]

, 2016
BackgroundResection of colorectal liver metastasis (CRLM) can be curative. Predicting which patients may benefit from resection, however, remains challenging. Some microRNAs (miRNAs) become deregulated in cancers and contribute to cancer progression.
D'Angelica, Michael I, Goodarzi, Hani, Jarnagin, William R, Kingham, T Peter, Konstantinidis, Ioannis T, Kuk, Deborah, Nguyen, Hoang CB, Sadot, Eran, Saltz, Leonard, Shia, Jinru, Tavazoie, Sohail F, Zhang, Steven, Zheng, Jian   +12 more
core   +1 more source